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a  b  s  t  r  a  c  t
Multiple  myeloma  (MM)  is composed  of an  array  of multiple  clones,  each  potentially  associated  with
different  clinical  behavior.  Previous  studies  focused  on  clinical  implication  of centrosome  ampliﬁcation
(CA)  in  MM  show  contradictory  results.  It  seems  that  the  role  of  CA  as well  as  CA  formation  in  MM differ
from  other  malignancies.  This  has brought  about  a  question  about  the  role  of  CA  positive  clone  which
is—is  it going  to be  a more  aggressive  clone  evolutionally  arising  under  pressure  of negative  conditionseywords:
entrosome ampliﬁcation
roliferation
lonal diversiﬁcation
ultiple myeloma
or  can  CA  serve  as a marker  of  cell  abnormality  and  lead  to cell  death  and further  elimination  of this
damaged  subpopulation?
This  current  review  is devoted  to the  discussion  of  the  existence  of  MM  subclones  with centrosome
ampliﬁcation  (CA),  its evolutionary  behaviour  within  intraclonal  heterogeneity  as  well  as its  potential
impact  on the  disease  progression  and  MM  treatment.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Cancer is frequently considered to be a disease of cell cycle.
ndeed, this is a complex multistep process, which results from
ynamic reprogramming of the genome and leads to autonomous
ell behavior, including uncontrolled proliferation.
∗ Corresponding author at: Department of Haematooncology, Faculty of Medicine,
niversity of Ostrava, Czech Republic.
E-mail address: f.kryukov@gmail.com (F. Kryukov).
ttp://dx.doi.org/10.1016/j.critrevonc.2015.10.019
040-8428/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).Historical knowledge of heterogeneity in cancer, both from a
histopathological and genetic perspective coupled with a large
number of recent studies document extensive intratumoral genetic
heterogeneity in a wide range of malignancies including mono-
clonal gammopathies (Lengauer et al., 1998; Swanton, 2012; Burrell
and Swanton, 2014a). Brieﬂy, heterogeneity occurs ﬁrst at the cellu-
lar level (intercellular heterogeneity) but with selective outgrowth
of any given cell clone, varying degrees of clonal heterogeneity
may  arise. Subclones may  expand and evolve in a sequential linear
fashion, or otherwise may  continue to diverge, following branched
evolutionary trajectories (Burrell and Swanton, 2014b).
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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Multiple myeloma (MM)  is composed of an array of multiple
lones, each potentially associated with different clinical behav-
or. Some clones will be more proliferative and associated with
apid clinical progression and early relapse, while others may  be
ess proliferative or even out of cycle and associated with late
elapse (Morgan et al., 2012). These cellular fractions are hetero-
eneous in their mutational and chromosomal makeup as well as
iological features that determine the variability in tumor pro-
ression, clinical aggressiveness and sensitivity to therapy seen
n cancer (Melchor et al., 2014). The current review is devoted to
he discussion of the existence of MM subclones with centrosome
mpliﬁcation (CA), its evolutionary behaviour within intraclonal
eterogeneity as well as its potential impact on the disease pro-
ression and MM treatment.
. Centrosome ampliﬁcation in multiple myeloma
.1. Centrosome ampliﬁcation is a concomitant event of
ncontrolled proliferation, but not in multiple myeloma?
Centrosomes are small cell organelles composed of two cylin-
rically shaped centrioles surrounded by pericentriolar material in
 normal mitotic cell. The centrosome function is to direct mitotic
ipolar spindles in a process that is essential for accurate chro-
osome segregation during mitosis (Hinchcliffe and Sluder, 2001;
ramer et al., 2002). Centrosomes duplicate once per cell cycle
nd each daughter cell receives one centrosome upon cytokinesis
Rebacz et al., 2007).
Centrosome dysfunction is particularly prevalent in tumors in
hich the genome has undergone extensive structural rearrange-
ents and chromosome domain reshufﬂing (Pihan, 2013). It is now
ell established that centrosome abnormalities in cancer corre-
ate closely with chromosome instability (CIN) (Pihan et al., 1998).
owever, correlative evidence does not establish causality. Con-
ersely, there is evidence that centrosome contributes to cell-cycle
egulation and checkpoints (Wang et al., 2009; Mikule et al., 2007).
hese observations place centrosome abnormalities at the earliest
tages of cancer development (Pihan, 2013). Nevertheless, despite
heir common occurrence, and perhaps due to the heterogeneity of
entrosome abnormalities in cancer, it has been difﬁcult to deter-
ine the origin of centrosome abnormality, whether centrosome
bnormalities are caused by primary intrinsic centrosome defects,
r are the consequence of dysfunction of other cellular processes
hat lead to the accumulation of normally replicated centrosomes
Nigg, 2002; Storchova and Pellman, 2004). At present, centrosome
bnormalities have become very alluring investigative targets in
he prospects of utilizing these defects as biomarkers and targets
or cancer speciﬁc therapy.
Most cells in adult organisms do not divide and are maintained
t a post-mitotic stage, which is also known as quiescence. Since
ne of the fundamental hallmarks of all cancer process is uncon-
rolled proliferation (Hanahan and Weinberg, 2000; Hanahan and
einberg, 2011), then a question arises, if tumors often origi-
ate from adult tissues in which most cells are quiescent, how do
umor cells undergo uncontrolled proliferation? Thus, the prolifer-
tive advantage of tumor cells or certain tumor clones arises from
heir ability to bypass quiescence. This question is very relevant for
yeloma cells when taking into consideration that primary plasma
ells are terminally differentiated and no longer divide—they are
rrested in the G1 phase of cell cycle as intermediates in plasma-cell
ifferentiation, which is a consequence of transformation (Tourigny
t al., 2002). Centrosome ampliﬁcation as well as aneuploidy rep-
esents the concomitant events of uncontrolled proliferation in
arcinogenesis. In spite of this, unlike other tumors, proliferation
ndex in MM is predominantly low and chromosomal instabilitylogy/Hematology 98 (2016) 116–121 117
and supernumerary centrosomes are the typical feature of multi-
ple myeloma. Moreover, they represent an early event in myeloma
genesis (Chng et al., 2006a).
2.2. Centrosome ampliﬁcation in MM: is it a good sign or a bad
omen?
There is a question that arises about the role of CA positive
clone—is it going to be a more aggressive clone evolutionally arising
under pressure of negative conditions or can CA lead to cell death
and further elimination of this damaged subpopulation?
It was shown by Sato et al. (2000) that centrosome overdu-
plication may  be a critical event that leads to mitotic failure and
subsequent cell death following crucially damaging inﬂuence and
that it represents a mechanism that defends organisms from abnor-
mal  cell accumulation.
This suggestion seems logical, considering that dysfunctional
or supernumerary centrosomes will either impede cell division or
cause multipolar divisions, which most frequently lead to mitotic
catastrophe. Neither of these phenotypes would be expected to
favour the clonal expansion of a tumor cell (Nigg, 2002). In our
opinion, the same statement should coincide with aneuploidy and
chromosomal instability should be initially detrimental towards
tumor development. The frequent aneuploidy observed in human
tumors may  remain in some cases as a ﬁngerprint of original
“oncogene-induced mitotic stress” chromosomal instability, gen-
erated by loss of tumor suppressors (Malumbres, 2011). Analyses of
human tumors have revealed a strong positive correlation between
centrosomal abnormalities and aneuploidy, which has been fre-
quently used to support a possible causal role of chromosomal
instability in tumor formation. However, anti-proliferative effect
of aneuploidy still leaves an open question of the function of
aneuploidy, if it is oncogenic or tumor suppressive (Holland and
Cleveland, 2009; Nicholson and Cimini, 2015). Thus, mitoses with
multipolar spindles are inherently inefﬁcient, exhibiting a high rate
of intramitotic (mitotic catastrophe) (Vitale et al., 2011; Castedo
et al., 2004; Vakifahmetoglu et al., 2008), post-mitotic cell death
(Varmark et al., 2009), or senescence (Andreassen et al., 2001), hin-
dering tumor growth and acting as tumor suppressors rather than
tumor promoters (Ganem et al., 2009; Weaver and Cleveland, 2007;
Weaver et al., 2007).
In our previous study, we showed that a better 2-years over-
all survival (OS) was  indicated for newly diagnosed patients with
apparent CA positive clone. In addition, CA as a prognostic factor
was relevant for disease-related death cases that occurred within
two years after diagnosis (Dementyeva et al., 2013). Presumably,
these ﬁndings could be explained according to the assumption
that mitotic aberrations associated with numerical and functional
abnormalities of centrosomes trigger spindle checkpoints, leading
to mitotic catastrophe and cell death (Fukasawa, 2007). In these
cells with CA, the threshold of apoptosis activation induced by
drugs (Lee et al., 2010) or radiation (Saito et al., 2008) may  be
much lower. Illusive contradiction with ﬁndings of Chng et al. was
discussed in our previous publication (Dementyeva et al., 2013).
2.3. Centrosome ampliﬁcation in MM: proliferation activity and
apoptotic puzzle
Importantly, in those tumor types where CIN is present, there is
a signiﬁcant correlation between the CIN phenotype and poor prog-
nosis (Pinto et al., 2015; Hveem et al., 2014), which suggests that
chromosome imbalance might speciﬁcally contribute to aggressive
or metastatic cancer (Carter et al., 2006; Perez de Castro et al., 2007).
However, in the case of multiple myeloma, hyperdiploid-type is
associated with better survival compared to nonhyperdiploid-MM
(Chng et al., 2006b). We  are inclined to think that such statements
118 E. Kryukova et al. / Critical Reviews in Oncology/Hematology 98 (2016) 116–121
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aFig. 1. Apoptotic failure a
bout CIN and CA, which are in agreement with high-proliferative
umors, including strong correlation and poor prognosis, are not
elevant for MM.  As it was mentioned above, MM is characterized
ith very low proliferative index of malignant plasma cells (PCLI)
nd even the highest proliferative clone PCLI hardly reaches 3%
Durie et al., 1980). It has been suggested that the accumulation
f MM cells in the bone marrow has mainly caused an enhanced
C proliferation due to dysregulation of PC apoptosis (Chen-Kiang,
003). Thus, the lower CA positive cells threshold to apoptosis
nduced by drugs or radiation seems to be a reasonable explana-
ion for better prognosis of patients with dominant CA positive
yeloma clone.
It is not clear which mechanism causes the accumulation of
entrosome that may  eventually lead cells to apoptosis. It is rea-
onable to assume that nuclear damage resulting from multiple
entrosomes could be a trigger for apoptosis (Sato et al., 2000).
 group of Qing Z. Kong suggests that the centrosome functions
pstream of the mitochondrial proteins (such as cytochrome c and
cL-2 family) and other apoptotic molecules (such as BH3-only pro-
eins and caspase-8, Noxa, TR3, BAX, BAK, and BID). p53, which
lays an important role in cell cycle regulation and apoptosis (Igney
nd Krammer, 2002; Moll and Zaika, 2001; Ryan et al., 2001), was
ound among other P53 cytoplasmic location in the centrosomes
Morris et al., 2000) and mitochondria (Moll and Zaika, 2001). When
xposed to stress signals, a fraction of induced p53 protein rapidly
ranslocate to mitochondria at the onset of p53-dependent apopto-
is (Sansome et al., 2001; Marchenko et al., 2000; Kong, 2003).
.4. Accumulation of oncogenic stress: quantity to quality
Centrosome ampliﬁcation leads to multipolar divisions and
ost of them that occur in tumors probably reﬂect non-productive
vents. However, an occasional division might give rise to proge-
ies with a genetic constitution that favors survival in a changing
hysiological environment. Nevertheless, the importance of such
are events should not be underestimated as they may  be cru-
ial in generating cells with properties signiﬁcantly different from
he main tumor population, which underscores, at least partly,
he typical punctual evolution of the tumor genome (Baca et al.,
013; Heng et al., 2011; Malhotra et al., 2013; Navin et al., 2011;
hen, 2013). Selective pressure might arise, for instance, through
ncreasing hypoxia or nutritional deprivation in a growing tumor
ass, or through the presence of a chemotherapeutic drug (Nigg,
002). Damage of G2/M and G1/S cell cycle checkpoints ﬁnally pro-
ides the proliferating clone with a more aggressive armament,
hich includes growth factors and stromal independence, absence
f response to differentiation signals and absence of polarity. This
s conﬁrmed by the fact that the fraction of cells with centrosome
bnormalities progressively increases with advancing tumor stages
Pihan et al., 2001; Lingle et al., 2002; Shono et al., 2001). This
lone probably manages to survive with high levels of chromosomal
nstability, and this alteration usually correlates with poor prog-
osis. How these tumor cells deal with the adverse effects of this
ontinuous instability remains an important question (Manchado
nd Malumbres, 2011).ersion of CA implication.
There is a suggestion that the combination of structural and
numerical chromosome abnormalities triggered by centrosome
dysfunction, ultimately leads to gene reshufﬂing and reprogram-
ming of the CA positive clone genome. Ongoing gene reshufﬂing
reprograms the genome for continuous growth, survival, and eva-
sion of the immune system (Pihan, 2013).
As long as myeloma cells undergo cell cycle infrequently, it is
supposed that dysregulation of apoptosis is mainly responsible for
the accumulation of MM cells in the bone marrow (Chen-Kiang,
2003).
However, accumulation of cancerogenic events stress with
subsequent genome reshufﬂing ﬁnally leads to the disabling of
apoptotic control. Thus, myeloma clone with CA and CIN lose
high sensitivity to apoptotic signals and are no longer eliminated
by negative selection. In our opinion, after such transformation,
CA positive clone loses its vulnerability and to the contrary, CA
becomes an additional factor that supports CIN accumulation dur-
ing subsequent disease progression (Fig. 1).
Another mechanism leading to the escape of apoptotic death
that has been developed by myeloma cells represents a cluster for-
mation. Reconﬁguring of multipolar spindles into bipolar ones prior
to anaphase enables bipolar division of myeloma cells in spite of
supernumerary centrosomes (Kramer et al., 2011). Conceptually,
centrosomal clustering emerges as a powerful adaptive survival
strategy that enables cells to successfully divide in the presence of
supernumerary centrosomes. Nevertheless, the clinical role of such
mechanism in MM aberrant clone survival and evolution might be
a rewarding area for further research.
Accumulation of cancerogenic events with subsequent genome
reshufﬂing ﬁnally leads to disabling of apoptotic control. After
“apoptotic threshold” is reached, CA positive clone lose high sensi-
tivity to apoptotic signals and are no longer eliminated by negative
selection.
2.5. Treatment interference: not obvious but expected
Proliferative clones associated with early relapse could be totally
eradicated and cured by cell cycle active chemotherapy. However,
slowly growing clones that are out of cycle would survive such
treatment and may  persist, becoming responsible for late relapse.
These clones are the target of consolidation and maintenance treat-
ment. In evolutionary context, therapy can be considered as a
selective pressure differentially acting on the myeloma clones and
impacting on their chances of survival. In this context, the criti-
cal mechanism for tumor progression is the competition between
individual clones for the same microenvironmental ‘niche’ and the
avoidance of selective pressures exerted by the immune system,
combined with the process of adaptation and natural selection
(Greaves and Maley, 2012). Once treatment has been initiated, the
selective pressures change and possibly the evolution of the tumor
is enhanced by exposure to treatment.
In our study, CA lost their positive clinical implication in cohorts
of relapsed patients (Dementyeva et al., 2013). We  suppose that the
loss of CA positive clinical implication may  be explained with pri-
mary treatment-driven effect on apoptotic control. Consequently,
such an effect leads to decrease of pro-apoptotic effect on cen-
E. Kryukova et al. / Critical Reviews in Oncology/Hematology 98 (2016) 116–121 119
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rosome ampliﬁcation. Alternatively, CA positive clone will be
liminated due to treatment pressure (Fig. 2).
CA positive clone with safe pro-apoptotic effect on centrosome
mpliﬁcation (light grey) is eliminated due to treatment pressure.
. CA negative clone (dark grey) gets evolutionary beneﬁts and
ecomes dominant. B. CA positive clone with lost pro-apoptotic
ffect on centrosome ampliﬁcation (dark grey) gets evolutionary
eneﬁts and becomes dominant.
Heterogeneous clones will have a different sensitivity to individ-
al chemotherapeutic agents. Proliferative clones are often more
ensitive to cell cycle active chemotherapy and can be fully erad-
cated, whereas indolent clones are less sensitive and may  be
ore susceptible to active drugs, such as immunomodulatory drugs
IMiDs) or proteasome inhibitors (Brioli et al., 2014).
. Questions and perspectives
In our studies, as in previous ones, abnormal centrosome struc-
ure was predominantly seen in MM plasma cells. We  have not
nalyzed quantitative relations between cells that are present with
bnormal structures and conﬁgurations of centrosome and cells
ith CA. The inﬂuence of abnormal structures and conﬁgurations
f centrosomes on myeloma cell survival and its possible clinical
mpact is still not elucidated, but it is deﬁnitely worth studying.
Another direction for further studies is the role of centrosome
ontrolling genes. In our previous study, we used gene expression
roﬁling to analyze a set of genes involved in the formation of
entrosome abnormalities in MM.  We  identiﬁed a gene pattern,
hich was used as a display of molecular heterogeneity with an
mpact on myeloma pathogenesis (Kryukov et al., 2013a). Previ-
us studies have shown that gene expression-based centrosome
ndex (CI), calculated from the expression of three centrosome
tructural proteins and components of the pericentriolar material
centrin, pericentrin and -tubulin) is associated with poor prog-
ostic genetic subtypes and portends short survival (Chng et al.,
006a; Chng et al., 2008). Our ﬁndings are in concordance with the
forementioned results. However, we showed preferential impact
f functional but not structural genes in the formation of centro-
ome abnormality. In summary, these ﬁndings are in concordance
ith the hypothesis about massive and complex genes interaction
e-settings during plasma cell malignant transformation (Kryukov
t al., 2013b).
In the meantime, another question of clinical signiﬁcance is
hether chromosomal unstable cells with centrosome ampliﬁ-
ation are more or less sensitive to antitumor drug induced cell
eath, since CIN and CA are common characteristics of tumor cells,
articularly myeloma cells. Moreover, it is embarrassing even to
nticipate the possibilities of CA clonal behavior and subsequent
lonal evolution after bone marrow transplantation.e clone in multiple myeloma.
In conclusion, we  assume that centrosome ampliﬁcation and
their role in MM clonal architecture represents a part of com-
plex process including mitotic dysregulation, apoptotic failure and
chromosome instability. It is not still clear where the driver and
passenger disorders are hidden. Nevertheless, the described facts
in this offered review give us possibility to suspect that the presence
of centrosome ampliﬁcation can inﬂuence clinical presentations as
well as the clonal evolution during MM development. It is suggested
that centrosome ampliﬁcation accomplished with safe apoptotic
system will reset cell cycle and make such CA clone more sen-
sitive to pro-apoptotic signals. In contrast, in case of an affected
apoptotic response, CA will cause severe genomic instability, which
evade apoptosis despite being induced, and may eventually develop
a clone with even more aggressive phenotype. This pattern of
evolution will lead to inefﬁciency of therapy to eradicate these
populations that place them at the root of relapse. Thus, it is not
possible to explicitly determine the direction of CA clone develop-
ment as long as it can represent a wide clone variety, especially
under therapeutic pressure. Thus, for prognostic and/or predictive
potential evaluation, two  systems should be analyzed in complex:
general MM clonal architecture as a macro-system and genomic
disorder of each separate clone as a micro-system. These theoret-
ical concerns require further investigations before this cell target
may  be considered for clinical utility.
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